Evidence map›Paper›PMID 34250401›Full record

ArticleJCO precision oncology2021

Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With

Dorothea Hanf, Christoph Heining, Karin Laaber, Heiner Nebelung, Sebastian Uhrig, Barbara Hutter, Arne Jahn, Daniela Richter, Daniela Aust, Friederike Herbst and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dorothea HanfDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.ORCID 0000-0001-9636-5378
Christoph HeiningDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.
Karin LaaberTranslational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-3666-2658
Heiner NebelungDepartment of Radiology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.ORCID 0000-0002-7303-6691
Sebastian UhrigDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-0068-5957
Barbara HutterDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Arne JahnDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.ORCID 0000-0003-1045-1908
Daniela RichterDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.
Daniela AustInstitute of Pathology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.ORCID 0000-0002-4867-8852
Friederike HerbstTranslational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-2167-750X
Stefan FröhlingGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-7907-4595
Hanno GlimmDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and DKFZ Dresden, Dresden, Germany.
Gunnar FolprechtNational Center for Tumor Diseases (NCT), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-9321-9911

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAnilidesBenzamidesDrug Resistance, NeoplasmETS Translocation Variant 6 ProteinGene FusionHumansIndazolesMaleMutationProto-Oncogene Proteins c-etsPyridinesReceptor, trkCRepressor ProteinsThyroid NeoplasmsTreatment OutcomeAnilidesBenzamidescabozantinibentrectinibETS Translocation Variant 6 ProteinIndazolesProto-Oncogene Proteins c-etsPyridinesReceptor, trkCRepressor Proteins

Identifiers

PMID34250401
PMCPMC8232550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.